Arrakis' oral therapies targeting disease-driving RNA in myotonic dystrophy have shown promise in preclinical studies.
Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...
Columnist Shalom Lim describes a moving performance at the Enabling Lives Festival in Singapore, an example of the power of ...
The case is reported of a young woman who began having DMD symptoms before getting pregnant, allowing her to receive genetic ...
Based on the positive findings from the Phase 1/2 study, Genethon is planning to launch Phase 3 testing of GNT0004 next year.
Columnist Patrick Moeschen, who lives with limb-girdle muscular dystrophy, explains why controlling what he can is so ...
Columnist Robin Stemple knows his walker should help prevent falls, but it didn't work out that way on a simple maneuver to ...
Couch shopping made columnist Betty Vertin discover she was focused on her three children with DMD rather than the rest of her family.